Skip to main content
INBP
OTC Life Sciences

Integrated BioPharma Q1 Swings to $691K Net Loss as Sales Fall 21.9%

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Food & Beverage Stocks · Consumer
Sentiment info
Negative
Importance info
7
Price
$0.165
Mkt Cap
$5.129M
52W Low
$0.138
52W High
$0.42
52W Position info
20% above low
Off High info
61% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

INBP sits 20% above its 52-week low of $0.138 on light trading volume (0.1× avg).

Summary

Integrated BioPharma swung to a $691K net loss on a 21.9% sales decline, with gross margin turning negative and $1.2M of cash used in operations. Cash fell to $3.1M, leaving the undrawn PNC revolver as the key liquidity source.

Updates

  1. · Wiseek News — Integrated BioPharma's quarterly revenue fell 22% to $9.9M from $12.7M a year earlier, with top two customers at 88% of revenue versus 87%.

    • Operating loss was $1.0M versus $0.2M operating income in the prior-year quarter.

Key Events · Earnings and Guidance · INBP

  • Q1 Sales Drop 21.9%

    Net sales fell to $9,913 thousand from $12,689 thousand, driven by a $2,384 thousand decline in purchases by Life Extension within Contract Manufacturing.

  • Gross Margin Turns Negative

    Cost of sales of $10,025 thousand exceeded revenue, producing a $112 thousand gross loss versus $1,019 thousand gross profit a year earlier; net loss was $691 thousand versus $123 thousand net income.

  • Operating Cash Burn of $1.2M

    Net cash used in operating activities was $1,219 thousand versus $1,301 thousand provided a year earlier, and cash fell to $3,116 thousand from $4,471 thousand at June 30, 2026.

  • PNC Covenant Miss Awaits Waiver

    The company did not meet its 1.10 to 1.0 fixed charge coverage ratio at June 30, 2026 and has requested a waiver from PNC; no debt was outstanding under the lines of credit at September 30, 2026.


Analysis · INBP · Life Sciences

The quarter deteriorated sharply: sales fell 21.9% to $9.9M, cost of sales exceeded revenue, and the company posted a $112K gross loss versus a $1.0M gross profit a year ago. The revenue drop is concentrated — Life Extension purchases fell $2.4M — and with two customers still at 88% of consolidated sales, there is little cushion. Cash fell to $3.1M and operations burned $1.2M in the quarter, so the $4.25M undrawn PNC revolver is now the main liquidity backstop; management says operations plus that facility cover requirements through November 13, 2027. The company also disclosed it missed its PNC fixed charge coverage ratio at June 30, 2026 and is awaiting a waiver.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INBP was trading at $0.17 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.14 to $0.42. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INBP - Latest Insights

INBP
Oct 28, 2026, 3:07 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.165
Real-time Price: $0.16514 info
Change: +$0.00014 (+0.08%) info
Market Cap: $5.129M info
INBP
Sep 25, 2026, 4:36 PM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $0.1837
Real-time Price: $0.16514 info
Change: -$0.01856 (-10%) info
Market Cap: $5.129M info
INBP
Jul 02, 2026, 10:37 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.1797
Real-time Price: $0.16514 info
Change: -$0.01456 (-8%) info
Market Cap: $5.129M info
INBP
May 08, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.250
Real-time Price: $0.16514 info
Change: -$0.08486 (-34%) info
Market Cap: $5.129M info
INBP
Apr 17, 2026, 4:17 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $0.280622
Real-time Price: $0.16514 info
Change: -$0.115482 (-41%) info
Market Cap: $5.129M info